Development of Vogt–Koyanagi–Harada Disease-like Uveitis during Treatment by Anti-programmed Death Ligand-1 Antibody for Non-small Cell Lung Cancer: A Case Report

References

• Davies M, Duffield EA. Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. Immunotargets Ther. 2017;6:51–71. doi:10.2147/itt.S141577.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi:10.1038/nrc3239.
   PubMed Web of Science ®Google Scholar
• Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group. J Immunother Cancer. 2017;5(1):95.doi:10.1186/s40425-017-0300-z.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714–1768.doi:10.1200/jco.2017.77.6385.
   PubMed Web of Science ®Google Scholar
• Dow ER, Yung M, Tsui E. Immune checkpoint inhibitor-associated uveitis: review of treatments and outcomes. Ocul Immunol Inflamm. 2020;1–9. doi:10.1080/09273948.2020.1781902.
   Web of Science ®Google Scholar
• Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects. Retina (Philadelphia, Pa). 2018;38(6):1063–1078. doi:10.1097/iae.0000000000002181.
   PubMed Web of Science ®Google Scholar
• Arai T, Harada K, Usui Y, Irisawa R, Tsuboi R. Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient. J Dermatol. 2017;44(8):975–976. doi:10.1111/1346-8138.13612.
   PubMed Web of Science ®Google Scholar
• Bricout M, Petre A, Amini-Adle M, et al. Vogt-Koyanagi-Harada-like syndrome complicating pembrolizumab treatment for metastatic melanoma. J Immunother. 2017;40(2):77–82. doi:10.1097/cji.0000000000000154.
   PubMed Web of Science ®Google Scholar
• Crosson JN, Laird PW, Debiec M, Bergstrom CS, Lawson DH, Yeh S. Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma. J Immunother. 2015;38(2):80–84. doi:10.1097/cji.0000000000000066.
   PubMed Web of Science ®Google Scholar
• Fujimura T, Kambayashi Y, Tanita K, et al. HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy. J Dermatol. 2018;45(6):735–737. doi:10.1111/1346-8138.14273.
   PubMed Web of Science ®Google Scholar
• Obata S, Saishin Y, Teramura K, Ohji M. Vogt-Koyanagi-Harada disease-like uveitis during nivolumab (Anti-PD-1 Antibody) treatment for metastatic cutaneous malignant melanoma. Case Rep Ophthalmol. 2019;10(1):67–74. doi:10.1159/000496682.
   PubMed Web of Science ®Google Scholar
• Wong RK, Lee JK, Huang JJ. Bilateral drug (ipilimumab)-induced vitritis, choroiditis, and serous retinal detachments suggestive of vogt-koyanagi-harada syndrome. Retin Cases Brief Rep. 2012;6(4):423–426. doi:10.1097/ICB.0b013e31824f7130.
   PubMedGoogle Scholar
• Yoshida S, Shiraishi K, Mito T, Sayama K. Vogt-Koyanagi-Harada-like syndrome induced by immune checkpoint inhibitors in a patient with melanoma. Clin Exp Dermatol. 2020;45(7):908–911. doi:10.1111/ced.14282.
   PubMed Web of Science ®Google Scholar
• Kurono Y, Takeda T, Kunimatsu Y, Tani N, Hashimoto I, Hirose K. Vogt-Koyanagi-Harada disease during chemoimmunotherapy for non-small cell lung cancer. Respirol Case Rep. 2020;8(3):e00545. doi:10.1002/rcr2.545.
   PubMed Web of Science ®Google Scholar
• Kikuchi R, Kawagoe T, Hotta K. Vogt-Koyanagi-Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy: a case report. BMC Ophthalmol. 2020;20(1):252. doi:10.1186/s12886-020-01519-5.
   PubMed Web of Science ®Google Scholar
• Sakata VM, da Silva FT, Hirata CE, de Carvalho JF, Yamamoto JH. Diagnosis and classification of Vogt-Koyanagi-Harada disease. Autoimmun Rev. 2014;13(4–5):550–555. doi:10.1016/j.autrev.2014.01.023.
   PubMed Web of Science ®Google Scholar
• Lavezzo MM, Sakata VM, Morita C, et al. Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes. Orphanet J Rare Dis. 2016;11:29. doi:10.1186/s13023-016-0412-4.
   PubMed Web of Science ®Google Scholar
• Sun X, Roudi R, Dai T, et al. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis. BMC Cancer. 2019;19(1):558.doi:10.1186/s12885-019-5701-6.
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–1034.doi:10.1084/jem.192.7.1027.
   PubMed Web of Science ®Google Scholar
• Qin W, Hu L, Zhang X, et al. The diverse function of PD-1/PD-L pathway beyond cancer. Front Immunol. 2019;10:2298. doi:10.3389/fimmu.2019.02298.
   PubMed Web of Science ®Google Scholar
• Teng F, Meng X, Kong L, Yu J. Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: a systematic review. Cancer Lett. 2018;414:166–173. doi:10.1016/j.canlet.2017.11.014.
   PubMed Web of Science ®Google Scholar
• Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131(5):647–652. doi:10.1016/s0002-9394(01)00925-4.
   PubMed Web of Science ®Google Scholar